Acropolis Investment Management LLC Invests $242,000 in Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Acropolis Investment Management LLC has acquired a new position in Aurinia Pharmaceuticals, purchasing 28,525 shares valued at approximately $242,000 during the second quarter.
• Analysts have a consensus rating of "Buy" for Aurinia Pharmaceuticals, with target prices ranging from $9.00 to $17.00.
• Insider activity remains significant, with Director Kevin Tang acquiring 200,000 shares for approximately $2.34 million recently, increasing his ownership stake.

Acropolis Investment Management LLC acquired a new position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 28,525 shares of the biotechnology company's stock, valued at approximately $242,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Deutsche Bank AG grew its position in shares of Aurinia Pharmaceuticals by 54.8% in the 4th quarter. Deutsche Bank AG now owns 142,869 shares of the biotechnology company's stock worth $1,283,000 after buying an additional 50,575 shares during the last quarter. Strs Ohio purchased a new stake in Aurinia Pharmaceuticals during the 1st quarter worth approximately $636,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Aurinia Pharmaceuticals by 3.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,314 shares of the biotechnology company's stock worth $685,000 after purchasing an additional 2,887 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in Aurinia Pharmaceuticals during the 1st quarter worth approximately $86,000. Finally, GAMMA Investing LLC grew its position in Aurinia Pharmaceuticals by 56.1% during the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 1,744 shares during the last quarter. Hedge funds and other institutional investors own 36.83% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Royal Bank Of Canada boosted their target price on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a research report on Friday, August 1st. HC Wainwright reissued a "buy" rating and set a $17.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $13.00.

Aurinia Pharmaceuticals Stock Performance

NASDAQ:AUPH opened at $13.07 on Tuesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23. The company has a fifty day moving average of $11.28 and a two-hundred day moving average of $9.18. The stock has a market capitalization of $1.72 billion, a PE ratio of 30.40 and a beta of 1.26. Aurinia Pharmaceuticals Inc has a fifty-two week low of $6.55 and a fifty-two week high of $13.44.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The company had revenue of $70.01 million for the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang bought 200,000 shares of Aurinia Pharmaceuticals stock in a transaction dated Tuesday, August 5th. The stock was acquired at an average cost of $11.68 per share, for a total transaction of $2,336,000.00. Following the completion of the transaction, the director directly owned 11,329,500 shares of the company's stock, valued at approximately $132,328,560. This represents a 1.80% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have bought 1,300,000 shares of company stock valued at $13,590,000 in the last ninety days. 12.20% of the stock is owned by corporate insiders.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.